THE INDIAN PHARMACIST Official Circular Pharmacy Logo THE INDIAN PHARMACISTLearn. Explore. Practise. Excel.
MEDICINE MONOGRAPH CODE: [11.16] ID: TIP-MED-000220 ⚠️ HIGH-ALERT / SPECIALIST SUPERVISION

Midazolam (Parenteral & Intranasal Rescue Protocol)

Active Ingredient / Scientific Identity: Midazolam • Class: Short-Acting Water-Soluble Imidazobenzodiazepine (Intranasal / Buccal / Parenteral Anticonvulsant & Sedative)

⚖️ Compare Profile
THE INDIAN PHARMACIST — Educational Reference Sheet
Profile: Midazolam (Parenteral & Intranasal Rescue Protocol) ([11.16] | ID: TIP-MED-000220) • Last Reviewed: 2026-11-10
Source URL: https://theindianpharmacist.com/medicine/11-16-midazolam-parenteral-intranasal-rescue-protocol/
Generic / Entity NameMidazolam (Parenteral & Intranasal Rescue Protocol) ([11.16])
Verified Indian Brands / RefGeneric Compendial Entry (No Commercial Brand Claimed)
Pharmacological ClassShort-Acting Water-Soluble Imidazobenzodiazepine (Intranasal / Buccal / Parenteral Anticon
Available Dosage FormsIntranasal Spray (Insed): 0.5 mg/puff or 1.25 mg/puff; Injection: 1 mg/mL (5 mL, 10 mL vials), 5 mg/mL (1 mL,
Regulatory ClassificationSchedule H1 Prescription Drug (Mandatory Red-Bordered Rx Warning & 3-Year Register un
Key Warning & Review DateRenal: eGFR <30 mL/min: Active alpha-1-hydroxymidazolam glucuronide accumulates during prolonged ICU infusions -> prolonged c
Reviewed: 2026-11-10
Safety Matrix:⚖️ Legal Status: Schedule H1 Prescription Drug (Mandatory Red-Bordere🚨 Clinically High-Alert: Independent Dose & Route Verification Required

1. Clinical & Scientific Overview

Midazolam (Parenteral & Intranasal Rescue Protocol) (TIP-MED-000220, Reference Code [11.16]) is classified under Neurology & Antiepileptic Medicines (Ch 11) as a Short-Acting Water-Soluble Imidazobenzodiazepine (Intranasal / Buccal / Parenteral Anticonvulsant & Sedative). Within the Indian regulatory and compendial framework, it is governed under Schedule H1 Prescription Drug (Mandatory Red-Bordered Rx Warning & 3-Year Register under Rule 65 of Drugs Rules 1945).

Verified Indian Market Examples / Compendial Status:
Representative Indian Market Examples (Edition 2.7 Ch 11 [11.16], p. 147): Mezolam, Midaz, Fulsed, Insed (Nasal Spray) — Strengths & Dosage Forms: Intranasal Spray (Insed): 0.5 mg/puff or 1.25 mg/puff; Injection: 1 mg/mL (5 mL, 10 mL vials), 5 mg/mL (1 mL, 3 mL ampoules).
Representative Indian Market Examples (Edition 2.7 Ch 11 [11.16], p. 147): Mezolam, Midaz, Fulsed, Insed (Nasal Spray) — Strengths & Dosage Forms: Intranasal Spray (Insed): 0.5 mg/puff or 1.25 mg/puff; Injection: 1 mg/mL (5 mL, 10 mL vials), 5 mg/mL (1 mL, 3 mL ampoules).
Dosage Forms & Available Strengths:
Intranasal Spray (Insed): 0.5 mg/puff or 1.25 mg/puff; Injection: 1 mg/mL (5 mL, 10 mL vials), 5 mg/mL (1 mL, 3 mL ampoules).
Routes: Oral / Parenteral / Topical as specified by formulation

3. Mechanism of Action & Pharmacodynamics

Water-soluble at acidic pH (<4) in ampoule; converts at physiological pH (7.4) into highly lipophilic closed-ring structure that rapidly crosses blood-brain barrier to potentiate GABA-A receptors.

4. Therapeutic Indications & Evidence-Supported Uses

  • Pre-hospital and domiciliary emergency rescue of prolonged acute convulsive seizures (intranasal spray / buccal / IM)
  • procedural sedation
  • ICU mechanical ventilation sedation

🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.

5. Educational Dosage Context, Formulations & Administration

Educational Dosing & Regimen Summary: Adult: Status Epilepticus (when IV access unavailable): 10 mg IM single dose OR 10 mg buccal/intranasal. Procedural Sedation: 0.5-2 mg slow IV over 2 min, titrated (Elderly: start 0.5 mg). • Paediatric: Acute Seizure Rescue: Intranasal/Buccal 0.2 mg/kg (max 10 mg) divided equally between both nostrils; IM 0.15-0.2 mg/kg (max 10 mg).

Administration & Meal Timing: See Administration & Counselling below. | Standard clinical schedule per indication.

6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment

Absorption & Disposition:
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
Metabolism & Biotransformation:
Renal: eGFR <30 mL/min: Active alpha-1-hydroxymidazolam glucuronide accumulates during prolonged ICU infusions -> prolonged coma; reduce infusion rate by 50%. • Hepatic: Cirrhosis / Congestive heart failure: Reduced CYP3A4 clearance -> halve bolus and maintenance doses.
Elimination & Renal Adjustment:
Renal: eGFR <30 mL/min: Active alpha-1-hydroxymidazolam glucuronide accumulates during prolonged ICU infusions -> prolonged coma; reduce infusion rate by 50%. • Hepatic: Cirrhosis / Congestive heart failure: Reduced CYP3A4 clearance -> halve bolus and maintenance doses.
Hepatic Impairment Considerations:
Renal: eGFR <30 mL/min: Active alpha-1-hydroxymidazolam glucuronide accumulates during prolonged ICU infusions -> prolonged coma; reduce infusion rate by 50%. • Hepatic: Cirrhosis / Congestive heart failure: Reduced CYP3A4 clearance -> halve bolus and maintenance doses.

7. Contraindications, Precautions & High-Risk Warnings

Contraindications & Red-Flag Precautions:
  • Contraindications: Acute narrow-angle glaucoma, severe respiratory depression without ventilatory support, co-administration with potent CYP3A4 inhibitors (oral/high-dose). • Precautions: High-Alert ICU sedative; rapid IV bolus causes apnoea and hypotension; ensure resuscitation equipment and Flumazenil (0.2 mg IV) are immediately accessible.

Key Clinical Precautions: Renal: eGFR <30 mL/min: Active alpha-1-hydroxymidazolam glucuronide accumulates during prolonged ICU infusions -> prolonged coma; reduce infusion rate by 50%. • Hepatic: Cirrhosis / Congestive heart failure: Reduced CYP3A4 clearance -> halve bolus and maintenance doses.

8. Adverse Effects Profile

Common & Mechanism-Related Adverse Effects:
  • Nasal irritation (nasal spray), hiccups, drowsiness, anterograde amnesia.
  • Respiratory arrest, laryngospasm, hypotension, ICU delirium.
Serious / Dose-Limiting Adverse Effects:
  • Monitor for severe hypersensitivity, organ toxicity, or dose-limiting adverse events.

9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions

  • Ketoconazole / Itraconazole / Ritonavir / Clarithromycin (CYP3A4 inhibitors) -> drastically prolong sedation; Fentanyl / Propofol -> synergistic apnoea and hypotension

10. Clinical Monitoring, Patient Counselling & Storage

Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.

Pharmacist Patient Counselling Points:

  • Patient Counselling Checklist: For domiciliary nasal spray: train caregivers to prime pump, administer half the calculated puffs into each nostril during a seizure lasting >3-5 minutes, and place patient in recovery position.
  • Meal & Clock Timing Instruction: See Administration & Counselling below. (Standard clinical schedule per indication.)
  • Missed Dose Protocol: Take as soon as remembered unless close to next scheduled dose; never double the dose.
  • Geriatric Dispensing Pearl: Schedule: Schedule H | NLEM 2022: Yes | Compendia: IP 2026 / NFI 7th Ed 2026 / NLEM 2022 / CDSCO Schedule H / BNF 90th Ed

Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Intranasal Spray (Insed): 0.5 mg/puff or 1.25 mg/puff; Injection: 1 mg/mL (5 mL, 10 mL vials), 5 mg/mL (1 mL, 3 mL ampoules).

11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)

THE 12-STEP ORAL DRUG JOURNEY THROUGH THE HUMAN BODY (LADME) Note: IV bolus enters Step 6 directly (F = 100%); Sublingual & Transdermal routes bypass Step 4–5 Portal First-Pass Metabolism 1. Oral Administration • Tablet / Capsule swallowed • Gastric emptying to duodenum pH 1.5–3.5 (Stomach) 2. Disintegration & Dissolution • Tablet breaks into granules • API dissolves in GI fluid Noyes-Whitney Dissolution Rate 3. GI Epithelial Absorption • Crosses intestinal villi • Passive / Active / P-gp efflux Small Intestine (Large Surface Area) 4. Portal Circulation • Mesenteric veins → Portal vein • Delivers blood to liver sinusoids Pre-systemic Venous Conduit 5. First-Pass Metabolism • Gut & hepatic CYP450 extraction • High: GTN, Propranolol, Morphine Determines Bioavailability (F = f_a × (1-E_H)) 6. Systemic Circulation • Hepatic vein → IVC → Heart • Unbound vs Albumin-bound drug Only FREE drug is active 7–8. Tissue Distribution (Vd) • Capillary permeation to organs • Blood-Brain & Placental barriers Vd = Dose / C_0 (L or L/kg) 9. Target Site of Action • Receptors (GPCR, Ion channel) • Enzymes & Carrier Transporters Pharmacodynamic Effect (E_max, EC50) 10. Hepatic Biotransformation • Phase I (CYP450 Oxidation/Hydrolysis) • Phase II (Glucuronidation/Sulfation) Converts lipophilic drug → hydrophilic metabolite 11. Renal & Biliary Elimination • Nephron: Filtration + Secretion − Reabsorption • Biliary excretion & Enterohepatic recycling Total Clearance CL_tot = CL_renal + CL_hepatic 12. Excretion from the Body • Urine (Primary polar metabolite route) • Bile/Faeces, Expired Air, Sweat, Milk Elimination Half-Life t1/2 = (0.693 × Vd) / CL
svg-v339-01-adme-12-step-journey — 8.1 Complete 12-Step Journey of an Orally Administered Drug (ADME): Figure 8.1: The 12-step physiological journey of a typical orally administered solid dosage form through Liberation, Absorption, Distribution, Metabolism, and Excretion (LADME). Note: Parenteral (IV), sublingual, and inhalational routes bypass gastrointestinal absorption and/or hepatic first-pass metabolism.

12. Authoritative References, Regulatory Sources & Editorial Disclaimer

Primary Compendial & Guideline Reference: Indian Pharmacist Desk Reference — Professional Edition 2.7 (2026–27) • Ch 11 [11.16] (p. 147)

Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)

Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: HANDBOOK_SOURCE_CONTENT

Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.

← Back to All 644 Reference Profiles 📖 Explore 40 Knowledge Hub Articles → ✉️ Report Errata / Feedback
Educational Reference Notice: This printout from THE INDIAN PHARMACIST (https://theindianpharmacist.com/medicine/11-16-midazolam-parenteral-intranasal-rescue-protocol/, Last Reviewed: 2026-11-10) is an educational reference sheet for students and healthcare learners. It is NOT an official prescribing guideline or patient-specific treatment order.